imt.ie2h
Four-in-five Parkinson’s patients report sleep issues
More than four-in-five people with Parkinson’s disease have trouble sleeping, a significantly higher rate than the general population, new Irish-led research has found.
I have a chronic, incurable disease. Here’s how I deal with it and keep on enjoying life.
Resisting the reality of chronic illness can lead to emotional distress. Acceptance, on the other hand, can open the door to ...
Q&A: How a scientist helped ban a chemical connected to Parkinson's disease
The U.S. will ban nearly all uses of the common industrial cleaning agent, trichloroethylene (TCE), this year—more than 50 ...
Kentucky Today13h
Lawmaker files bill to establish Ky. Parkinson’s Disease Research Registry
London, has collaborated with the London-based advocacy group Parkinson's In Motion and The Michael J. Fox Foundation (MJFF) ...
New York establishes statewide Parkinson's registry to advance research
New legislation signed into law by Governor Kathy Hochul is positioning New York as a leader in Parkinson’s Disease research. The new bill establ ...
Parkinson's patients face increased depression, independence issues due to poor sleep
A new study by researchers at Ireland's Maynooth University, based on patient data gathered by the US-based Michael J. Fox ...
Independent.ie22h
Maynooth University study reveals how poor sleep affects Parkinson’s patients – with help from Michael J Fox’s foundation
Sleep problems are very common in people with Parkinson’s disease and are associated with poorer quality of life in patients, ...
The Corner3d
Michael J. Fox Foundation donates Grifols $21 million to research new diagnostic tools for Parkinson’s disease
Link Securities | The Catalan blood products company has received a $21 million grant from the Michael J. Fox Foundation (MJFF) for Parkinson’s Disease Research to identify plasma-based biomarkers ...
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
Anavex’s newest patent will be expected to remain in force at least until July 2039, not including any patent term extensions. It will expand and supplement the current ANAVEX®2-73 (blarcamesine) ...